Affiliation
Innovative Immunotherapies Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Hospital Scientific Institute, Via Olgettina 60, 20132, Milan, Italy.Issue Date
2015-01
Metadata
Show full item recordAbstract
The recent successes of clinical trials with T cells genetically modified with either clonal T cell receptors or chimeric antigen receptors have also highlighted their potential toxicities. The aim of this focused review was to describe the adverse events observed in these clinical trials and to link them to the complex biology of genetically targeted T cells. Finally, strategies to overcome these toxicities will be proposed and discussed, including the use of suicide genes and other innovative gene therapy strategies.Citation
Overcoming the toxicity hurdles of genetically targeted T cells. 2015, 64 (1):123-30 Cancer Immunol ImmunotherJournal
Cancer Immunology, ImmunotherapyDOI
10.1007/s00262-014-1641-9PubMed ID
25488419Type
ArticleLanguage
enISSN
1432-0851ae974a485f413a2113503eed53cd6c53
10.1007/s00262-014-1641-9
Scopus Count
Collections
Related articles
- Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
- Authors: Feldman SA, Assadipour Y, Kriley I, Goff SL, Rosenberg SA
- Issue date: 2015 Aug
- Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
- Authors: Di S, Li Z
- Issue date: 2016 Apr
- Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
- Authors: Zhang BL, Qin DY, Mo ZM, Li Y, Wei W, Wang YS, Wang W, Wei YQ
- Issue date: 2016 Apr
- Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China.
- Authors: Luo C, Wei J, Han W
- Issue date: 2016 Apr
- Safety Strategies of Genetically Engineered T Cells in Cancer Immunotherapy.
- Authors: Ren YB, Sun SJ, Han SY
- Issue date: 2018